Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-29, Stock:LLY, The news for the past five days is as follows:
2018-06-22: NEWS1: U.S. District Court rules in favor of Lilly's Alimta patent.NEWS2: U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit.NEWS3: Merck (MRK) Stock Up So Far This Year on Keytruda Strength.NEWS4: Merck (MRK) Stock Up So Far This Year on Keytruda Strength.NEWS5: Incyte (INCY) Announces Positive Results on Jakafi for GVHD.NEWS6: Incyte (INCY) Announces Positive Results on Jakafi for GVHD.NEWS7: Lilly Completes Acquisition of ARMO BioSciences.
2018-06-25: NEWS1: Merck (MRK) Presents New Data from Januvia Diabetes Studies.NEWS2: Merck (MRK) Presents New Data from Januvia Diabetes Studies.NEWS3: Lilly Wins Favorable Ruling From U.S. Court in Alimta Row.NEWS4: Lilly Wins Favorable Ruling From U.S. Court in Alimta Row.NEWS5: Lilly Wins Favorable Ruling From U.S. Court in Alimta Row.NEWS6: Lilly's Jardiance meets main goal of two diabetes trials.NEWS7: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS8: Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes.NEWS9: First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes.NEWS10: Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache.NEWS11: Eli Lilly: Humulin R U-500 Administered In Insulin Pump Shows Improved A1C.NEWS12: Eli Lilly: Humulin R U-500 Administered In Insulin Pump Shows Improved A1C.NEWS13: Boehringer Ingelheim & Eli Lilly: Empagliflozin Trials Meet Primary Endpoint.NEWS14: Boehringer Ingelheim & Eli Lilly: Empagliflozin Trials Meet Primary Endpoint.NEWS15: Eli Lilly To Present Phase 3 Data For Galcanezumab, Lasmiditan - Quick Facts.NEWS16: Eli Lilly To Present Phase 3 Data For Galcanezumab, Lasmiditan - Quick Facts.
2018-06-26: NEWS1: How Pfizer’s Valuation Compares.NEWS2: Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies.NEWS3: Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies.NEWS4: Merck's Keytruda Under FDA Review for Advanced Melanoma.NEWS5: Merck's Keytruda Under FDA Review for Advanced Melanoma.NEWS6: Lilly&apos;s Diabetes Drugs Meet Endpoints in Phase III Studies.NEWS7: Is Pfizer's Lead Growth Driver in Trouble?.NEWS8: Is Pfizer's Lead Growth Driver in Trouble?.NEWS9: Is Pfizer&apos;s Lead Growth Driver in Trouble?.NEWS10: See what the IHS Markit Score report has to say about Eli Lilly And Co..
2018-06-27: NEWS1: A Look at Eli Lilly’s Valuations on June 25.NEWS2: AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA).NEWS3: AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache.NEWS4: Top Research Reports for Amazon, Intel & Eli Lilly.NEWS5: Top Research Reports for Amazon, Intel & Eli Lilly.NEWS6: Top Research Reports for Amazon, Intel & Eli Lilly.
2018-06-28: NEWS1: Lilly Confirms Date and Conference Call for Second-Quarter 2018 Financial Results Announcement.NEWS2: Eli Lilly’s Human Pharmaceuticals Business.NEWS3: The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern.NEWS4: The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern.NEWS5: Eli Lilly’s Business Segments: Growth and Trends.NEWS6: The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern.NEWS7: Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS9: Eli Lilly’s Q1 2018 Top Line Rose 9% to $5.7 Billion.NEWS10: Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients.NEWS11: ACRX Gets EC Nod, AQXP Tanks As LEADERSHIP 301 Fails, ZSAN Catches Eye.NEWS12: ACRX Gets EC Nod, AQXP Tanks As LEADERSHIP 301 Fails, ZSAN Catches Eye.

Answer: Decrease